Differences in the prognosis of HPV16-positive patients with squamous cell carcinoma of head and neck according to viral load and expression of P16

doi:10.1007/s00432-017-2531-2

Differences in the prognosis of HPV16-positive patients with squamous cell carcinoma of head and neck according to viral load and expression of P16

Communities & Collections

pcg.skipToMenu

Differences in the prognosis of HPV16-positive patients with squamous cell carcinoma of head and neck according to viral load and expression of P16

View Usage Statistics

Show full item record

dc.contributor.author	Biesaga, Beata	pl
dc.contributor.author	Mucha-Małecka, Anna	pl
dc.contributor.author	Janecka-Widła, Anna	pl
dc.contributor.author	Kołodziej-Rzepa, Marta	pl
dc.contributor.author	Szostek, Sława [SAP20000614]	pl
dc.contributor.author	Słonina, Dorota	pl
dc.contributor.author	Kowalczyk, Aleksandra	pl
dc.contributor.author	Halaszka, Krzysztof	pl
dc.contributor.author	Przewoźnik, Marcin	pl
dc.date.accessioned	2020-01-17T09:19:01Z
dc.date.available	2020-01-17T09:19:01Z
dc.date.issued	2018	pl
dc.identifier.issn	0171-5216	pl
dc.identifier.uri	https://ruj.uj.edu.pl/xmlui/handle/item/141740
dc.language	eng	pl
dc.rights	Udzielam licencji. Uznanie autorstwa 4.0 Międzynarodowa	*
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/pl/legalcode	*
dc.title	Differences in the prognosis of HPV16-positive patients with squamous cell carcinoma of head and neck according to viral load and expression of P16	pl
dc.type	JournalArticle	pl
dc.description.physical	63-73	pl
dc.abstract.en	Purpose To evaluate the impact of HPV16 load (VL-the number of virus genome copies per cell) and P16 expression on prognosis of patients with squamous cell carcinomas (SCCs) of head and neck (HN). Materials and methods HPV16 presence was assessed in the group of 109 patients with HNSCCs by quantitative polymerase chain reaction (qPCR). VL (assessed by qPCR) and P16 expression (evaluated by immunohistochemistry) were analysed only in the subgroup of HPV16-positive tumours. These features were correlated with 5-year overall survival (OS) and disease-free survival (DFS). Results HPV16 infection was found in 36 tumours (33.0%). Virus-positive patients had better OS and DFS than those without infection (P = 0.041 and 0.005). Among HPV16-positive HNSCCs, 18 (50.0%) had higher VL (median value > 6764.3 copies/cell) and 25 (73.5%) P16 over expression. The significant differences in OS and DFS (P = 0.008 and 0.004) were noticed according to VL, wherein 100% DFS was found for patients with higher VL. According to P16 expression, significant difference was found only for OS (P = 0.020). In multivariate analysis, VL (P = 0.045; HR = 2.795; CI 0.121-1.060) and the level of smoking (P = 0.023, HR = 2.253; CI 1.124-4.514) were independent factors affecting DFS of HPV16-positive patients. Conclusion On the basis of viral load, it is possible to differentiate prognosis of patients with HPV16-positive HNSCCs. In this subgroup, viral load has stronger prognostic potential than P16 expression.	pl
dc.subject.en	HNSCCs	pl
dc.subject.en	HPV16	pl
dc.subject.en	viral load	pl
dc.subject.en	P16 expression	pl
dc.subject.en	Prognosis	pl
dc.description.volume	144	pl
dc.description.number	1	pl
dc.description.points	25	pl
dc.identifier.doi	10.1007/s00432-017-2531-2	pl
dc.identifier.eissn	1432-1335	pl
dc.title.journal	Journal of Cancer Research and Clinical Oncology	pl
dc.language.container	eng	pl
dc.affiliation	Wydział Lekarski : Zakład Wirusologii	pl
dc.subtype	Article	pl
dc.rights.original	CC-BY; inne; ostateczna wersja wydawcy; w momencie opublikowania; 0	pl
dc.identifier.project	ROD UJ / OP	pl
dc.cm.id	85997
dc.cm.date	2020-01-07
.pointsMNiSW	[2018 A]: 25